SEC Company Response from SINOVAC BIOTECH LTD (SVA) (CIK 0001084201) (SVA) — Nov 1, 2005
SINOVAC BIOTECH LTD (SVA) (CIK 0001084201)
Date: Nov. 1, 2005 · CIK: 0001084201 · Accession: 0001127855-05-000668
AI Filing Summary & Sentiment
Referenced dates: OCTOBER 12, 2005, October 12, 2005
Show Raw Text
CORRESP 1 filename1.htm Untitled Page Vancouver Office: D E V L I N P.O. Box 12077 J E N S E N Suite 2550 Barristers & Solicitors 555 West Hastings St. Vancouver, B.C. Canada V6B 4N5 Tel: (604) 684-2550 Fax: (604) 684-0916 E-mail: mshannon@devlinjensen.com File Reference: 4020\045a Via EDGAR October 31, 2005 SECURITIES AND EXCHANGE COMMISSION 450 Fifth Street, N.W. Washington, D.C. U.S.A., 20549-0405 Attention: Mr. Mark Brunhofer, Staff Accountant, Division of Corporation Finance Dear Mr. Brunhofer: Re: Sinovac Biotech Ltd. (the “Company”) File No. 1-32371 INTENDED TIMING OF FILING OF AMENDED FORM 20-F IN ACCORDANCE WITH SEC COMMENT LETTER DATED OCTOBER 12, 2005 We are counsel for the above-referenced Company and are writing on its behalf. We are writing to advise the Securities and Exchange Commission (the “SEC”) that the Company was unable to file an amended Annual Report to the Form 20-F/A-2 that was filed on September 21, 2005, within 10 business days as set forth in the comments of the reviewing staff of the SEC ‘s comment letter dated October 12, 2005, and we anticipate that an amended Annual Report on Form 20-F/A-3 will be filed on or around November 22, 2005. Association of Law Corporations Securities and Exchange Commission October 31, 2005 Page 2 On behalf of the Company we sincerely thank and appreciate the SEC’s ongoing cooperation in this matter. Yours very truly, DEVLIN JENSEN Per: /s/ Mike Shannon MICHAEL T. SHANNON